InvestorsHub Logo
Followers 118
Posts 11972
Boards Moderated 0
Alias Born 12/18/2003

Re: Cindylou822 post# 209525

Friday, 05/27/2022 7:35:47 AM

Friday, May 27, 2022 7:35:47 AM

Post# of 233066
Our problem with CD10 , was that most of the patient admitted to the study were younger and generally healthy.
So at 3 days all on leronlimab reacted already with improvement , but at 14 days primary endpoint , most on a drug and placebo recovered ..

The only way to have successful study done in mild/moderate , if it will accept only patients at risk..
But that wasn't done..

But leronlimab is great ...

IMO as always..
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News